ATLANTA – In the search for good antibacterial targets, new sites on validated structures are one sweet spot. Because they are on previously targeted structures, they are in principle validated targets. At the same time, targeting novel sites can turn back the clock in the antibiotic resistance race, particularly if there is no cross-resistance with existing antibiotics that target the same structure.